SEOUL — LigaChem Biosciences announced on September 30 that it has entered into a joint research and technology in-licensing agreement with Abion to co-develop immunocytokine-antibody drug conjugate (iADC) candidates. The collaboration combines Abion's interferon-beta variant (IFN-β mutein)-based immunocytokines with LigaChem's proprietary antibody-drug conjugate (ADC) platform technology. Under the terms of the agreement, LigaChem Biosciences secures exclusive global develop

The U.S. FDA has approved Lyrfigtu (lirafugratinib), an FGFR2-selective inhibitor developed by HLB’s U.S. subsidiary, Elevar Therapeutics, as a second-line treatment for cholangiocarcinoma with FGFR2 fusions or rearrangements. The approval was based on the ReFocus clinical trial, which demonstrated an objective response rate (ORR) of approximately 46%. This marks HLB’s first U.S. new drug approval, following three Complete Response Letters (CRLs) for its liver cancer combinat

Apollon, a developer of needle-free continuous glucose monitoring (CGM) systems, announced on September 23 that it has raised KRW 5 billion (approximately $3.7 million) in a Series A funding round. This brings the startup's cumulative capital to over KRW 10 billion, combining private equity investment and government R&D grants. The financing round was led by SBI Investment, with strategic participation from Naver—ahead of the launch of its dedicated digital healthcare divisio